Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

IntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under syste...

Descripción completa

Detalles Bibliográficos
Autores: Soria, A, Calvo, M, Casas, M, Vidales, Z, Munoz-Martinez, S, Sapena, V, Puigvehi, M, Canillas, L, Guardeno, R, Gallego, A, Minguez, B, Horta, D, Clos, A, Montoliu, S, Roget, M, Reig, M, Vergara, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p1267
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/1267
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136164872&doi=10.3389%2ffonc.2022.829483&partnerID=40&md5=44ea15397266d82f8e75fa6f7b08372a
Access Level:acceso abierto
Palabra clave:sorafenib
elderly patients
hepatocellular carcinoma
overall survival
safety
outcome
id ES_7c8df8fdf2ec54df4e736338c587b4ac
oai_identifier_str oai:i3pt.fundanetsuite.com:p1267
network_acronym_str ES
network_name_str España
repository_id_str
spelling Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinomaSoria, ACalvo, MCasas, MVidales, ZMunoz-Martinez, SSapena, VPuigvehi, MCanillas, LGuardeno, RGallego, AMinguez, BHorta, DClos, AMontoliu, SRoget, MReig, MVergara, Msorafenibelderly patientshepatocellular carcinomaoverall survivalsafetyoutcomeIntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. MethodsRetrospective multicentre study of HCC patients aged >= 75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. ResultsThe study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS>0 (45.3 vs 34.7%; STD: 38.2) differed significantly between patients receiving low and full doses. Median OS was 15.4 months (18.2 in BCLC-B vs 13.6 in BCLC-C). OS was not modified by comorbidities, age or period with more expertise. ConclusionsSorafenib appears to be safe in elderly patients with HCC. This is the first study to characterize the profile of elderly patients to be considered for systemic treatment. These findings could be used as the reference profile for elderly candidates for atezolizumab-bevacizumab.FRONTIERS MEDIA SA2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/1267https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136164872&doi=10.3389%2ffonc.2022.829483&partnerID=40&md5=44ea15397266d82f8e75fa6f7b08372aFrontiers in OncologyISSN: 2234943Xreponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p12672026-06-21T15:30:37Z
dc.title.none.fl_str_mv Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
title Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
spellingShingle Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
Soria, A
sorafenib
elderly patients
hepatocellular carcinoma
overall survival
safety
outcome
title_short Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
title_full Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
title_fullStr Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
title_full_unstemmed Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
title_sort Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
dc.creator.none.fl_str_mv Soria, A
Calvo, M
Casas, M
Vidales, Z
Munoz-Martinez, S
Sapena, V
Puigvehi, M
Canillas, L
Guardeno, R
Gallego, A
Minguez, B
Horta, D
Clos, A
Montoliu, S
Roget, M
Reig, M
Vergara, M
author Soria, A
author_facet Soria, A
Calvo, M
Casas, M
Vidales, Z
Munoz-Martinez, S
Sapena, V
Puigvehi, M
Canillas, L
Guardeno, R
Gallego, A
Minguez, B
Horta, D
Clos, A
Montoliu, S
Roget, M
Reig, M
Vergara, M
author_role author
author2 Calvo, M
Casas, M
Vidales, Z
Munoz-Martinez, S
Sapena, V
Puigvehi, M
Canillas, L
Guardeno, R
Gallego, A
Minguez, B
Horta, D
Clos, A
Montoliu, S
Roget, M
Reig, M
Vergara, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv sorafenib
elderly patients
hepatocellular carcinoma
overall survival
safety
outcome
topic sorafenib
elderly patients
hepatocellular carcinoma
overall survival
safety
outcome
description IntroductionThe first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There is little evidence of efficacy and tolerability in elderly patients under systemic treatment. The aims of this study were to characterize the profile of elderly patients treated with sorafenib, assess their survival and safety profile in order to extrapolate their eligibility for systemic treatment. MethodsRetrospective multicentre study of HCC patients aged >= 75 years old treated with sorafenib from January 2008 to December 2019. Demographic data, baseline characteristics, and variables related to HCC and sorafenib were recorded. Overall survival (OS) and safety were analyzed. ResultsThe study included 206 patients from 11 hospitals, median age 77.9 years; 71.4% men and 62.6% stage Barcelona Clinic Liver Cancer- C (BCLC-C). The main causes of cirrhosis were hepatitis C (60.7%) and alcohol (14.7%). Most patients (84.5%) started with sorafenib 800mg and 15.5% at lower dosage. Arterial hypertension (AHT) (74.2 vs 62.2%; standardized mean differences (STD): 26) and baseline ECOG-PS>0 (45.3 vs 34.7%; STD: 38.2) differed significantly between patients receiving low and full doses. Median OS was 15.4 months (18.2 in BCLC-B vs 13.6 in BCLC-C). OS was not modified by comorbidities, age or period with more expertise. ConclusionsSorafenib appears to be safe in elderly patients with HCC. This is the first study to characterize the profile of elderly patients to be considered for systemic treatment. These findings could be used as the reference profile for elderly candidates for atezolizumab-bevacizumab.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/1267
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136164872&doi=10.3389%2ffonc.2022.829483&partnerID=40&md5=44ea15397266d82f8e75fa6f7b08372a
url https://i3pt.portalinvestigacion.com/publicaciones/1267
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136164872&doi=10.3389%2ffonc.2022.829483&partnerID=40&md5=44ea15397266d82f8e75fa6f7b08372a
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Oncology
ISSN: 2234943X
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411598715584512
score 15.81155

Similares en LA Referencia